[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
Mamounas EP, Untch M, Mano MS, et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE[J]. Ann Oncol, 2021, 32(8): 1005-1014.
|
[3] |
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials[J]. Lancet Oncol, 2021, 22(8): 1139-1150.
|
[4] |
Wang S, Xiong Y, Zhang Q, et al. Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer[J]. Brief Bioinform, 2021, 22(4):bbaa311.
|
[5] |
Iwamoto T, Kajiwara Y, Zhu Y, et al. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer[J]. Chin Clin Oncol, 2020, 9(3): 27.
|
[6] |
Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50.
|
[7] |
De Groot AF, Blok EJ, Charehbili A, et al. Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2019, 175(3): 605-615.
|
[8] |
Hamy AS, Pierga JY, Sabaila A, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer[J]. Ann Oncol, 2017, 28(9): 2233-2240.
|
[9] |
Asano Y, Kashiwagi S, Goto W, et al. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer[J]. Br J Surg, 2016, 103(7): 845-854.
|
[10] |
Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial[J]. Ann Oncol, 2014, 25(8): 1544-1550.
|
[11] |
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019[J]. Ann Oncol, 2019, 30(10): 1541-1557.
|
[12] |
Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study[J]. Ann Oncol, 2014, 25(3): 611-618.
|
[13] |
Eustace AJ, Madden SF, Fay J, et al. The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer[J]. Breast Cancer Res Treat, 2021, 187(3): 635-645.
|
[14] |
Hwang HW, Jung H, Hyeon J, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients[J]. Breast Cancer Res Treat, 2019, 173(2): 255-266.
|
[15] |
Ochi T, Bianchini G, Ando M, et al. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer[J]. Eur J Cancer, 2019, 118: 41-48.
|
[16] |
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J]. Ann Oncol, 2015, 26(2): 259-271.
|
[17] |
Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial[J]. JAMA Oncol, 2015, 1(4): 448-454.
|
[18] |
Dubsky P, Pinker K, Cardoso F, et al. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox[J]. Lancet Oncol, 2021, 22(1): e18-e28.
|
[19] |
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline[J]. J Clin Oncol, 2021, 39(13): 1485-1505.
|
[20] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-785.
|
[21] |
Paijens ST, Vledder A, De Bruyn M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era[J]. Cell Mol Immunol, 2021, 18(4): 842-859.
|
[22] |
Tran WT, Lu FI, Salgado R. Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer[J]. Expert Rev Anticancer Ther, 2021, 21(12): 1299-1301.
|
[23] |
Shou J, Zhang Z, Lai Y, et al. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis[J]. BMC Cancer, 2016, 16(1): 687.
|
[24] |
De Angelis C, Nagi C, Hoyt C C, et al. Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant Anti-HER2 therapy without chemotherapy[J]. Clin Cancer Res, 2020, 26(3): 738-745.
|
[25] |
Abe N, Matsumoto H, Takamatsu R, et al. Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer[J]. Virchows Arch, 2020, 476(5): 701-709.
|
[26] |
Hamy AS, Bonsang-Kitzis H, De Croze D, et al. Interaction between molecular subtypes and stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy[J]. Clin Cancer Res, 2019, 25(22): 6731-6741.
|
[27] |
Nuciforo P, Pascual T, Cortés J, et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade[J]. Ann Oncol, 2018, 29(1): 170-177.
|
[28] |
Hughes E, Scurr M, Campbell E, et al. T-cell modulation by cyclophosphamide for tumour therapy[J]. Immunology, 2018, 154(1): 62-68.
|
[29] |
Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells[J]. Clin Cancer Res, 2008, 14(8): 2413-2420.
|
[30] |
Goto W, Kashiwagi S, Asano Y, et al. Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy[J]. ESMO Open, 2018, 3(6): e000305.
|